TY - JOUR
T1 - Antenatal maternal antidepressants drugs affect S100B concentrations in fetal-maternal biological fluids
AU - Bellissima, Valentina
AU - Visser, Gerard H.A.
AU - Ververs, Tessa F.
AU - van Bel, Frank
AU - Termote, Jacqueline U.M.
AU - van der Heide, Marja
AU - Gazzolo, Diego
N1 - Publisher Copyright:
© 2015 Bentham Science Publishers.
PY - 2015/1/1
Y1 - 2015/1/1
N2 - Introduction: Antidepressant treatment during pregnancy is speedily increasing in developed countries and this phenomenon has occurred without firm evidence on safety and/or efficacy. Aims: The present study investigated from mid-trimester of pregnancy up to 24 hours after birth the pattern of a brain damage marker, namely S100B, in maternal fetal and neonatal biological fluids of pregnant women and their newborns antenatally treated by antidepressant drugs such as selective serotonin re-uptake inhibitors (SSRI). Methods: we conducted an observational study on 75 pregnant women treated in the mid –third trimester by antidepressant drugs and 231 healthy pregnancies. S100B concentrations were measured at 7 predetermined monitoring time-points before, during and after treatment in maternal, fetal and neonatal biological fluids and correlated with neurological follow-up at 7 days from birth. Results: In SSRI group S100B concentrations were significantly higher in SSRI than controls (P<0.001, for all) in maternal blood, in amniotic fluid, in arterial and venous cord blood and at 24-h from birth. Highest (P<0.05) S100B levels were found in SSRI infants showing major neurological symptoms at 7-d follow-up. Conclusion: The present data on increased S100B levels in maternal, fetal and neonatal biological fluids suggest that SSRI administration although beneficial to the mother, presents some risks for the infant.
AB - Introduction: Antidepressant treatment during pregnancy is speedily increasing in developed countries and this phenomenon has occurred without firm evidence on safety and/or efficacy. Aims: The present study investigated from mid-trimester of pregnancy up to 24 hours after birth the pattern of a brain damage marker, namely S100B, in maternal fetal and neonatal biological fluids of pregnant women and their newborns antenatally treated by antidepressant drugs such as selective serotonin re-uptake inhibitors (SSRI). Methods: we conducted an observational study on 75 pregnant women treated in the mid –third trimester by antidepressant drugs and 231 healthy pregnancies. S100B concentrations were measured at 7 predetermined monitoring time-points before, during and after treatment in maternal, fetal and neonatal biological fluids and correlated with neurological follow-up at 7 days from birth. Results: In SSRI group S100B concentrations were significantly higher in SSRI than controls (P<0.001, for all) in maternal blood, in amniotic fluid, in arterial and venous cord blood and at 24-h from birth. Highest (P<0.05) S100B levels were found in SSRI infants showing major neurological symptoms at 7-d follow-up. Conclusion: The present data on increased S100B levels in maternal, fetal and neonatal biological fluids suggest that SSRI administration although beneficial to the mother, presents some risks for the infant.
KW - Brain injury
KW - Fetal brain
KW - Maternal depression
KW - S100B
KW - SSRI
KW - Teratology
UR - http://www.scopus.com/inward/record.url?scp=84924177445&partnerID=8YFLogxK
U2 - 10.2174/1871527314666150116114033
DO - 10.2174/1871527314666150116114033
M3 - Article
C2 - 25613501
AN - SCOPUS:84924177445
SN - 1871-5273
VL - 14
SP - 49
EP - 54
JO - CNS and Neurological Disorders - Drug Targets
JF - CNS and Neurological Disorders - Drug Targets
IS - 1
ER -